The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform
Antonia M Mangues - One of the best experts on this subject based on the ideXlab platform.
-
prevalence and clinical impact of recreational Drug Consumption in people living with hiv on treatment a cross sectional study
BMJ Open, 2017Co-Authors: Noe Garin, Beatriz Zurita, Cesar Velasco, Anna Feliu, Mar Gutierrez, Montserrat Masip, Antonia M ManguesAbstract:Objectives Drug interactions, poor adherence to medication and high-risk sexual behaviour may occur in individuals with HIV using recreational Drugs. Thus, we aimed to assess the prevalence of recreational Drugs use and to explore its clinical impact in HIV patients on treatment. Methods Observational, cross sectional, study conducted in a 700 bed university hospital, Barcelona, Spain. A total of 208 adults living with HIV on treatment were included. A questionnaire was administered by clinical pharmacists, including evaluation of sociodemographic variables, past 12-month Drug Consumption, adherence to antiretrovirals (Simplified Medication Adherence Questionnaire) and high-risk sexual behaviour (condomless sex/multiple partners). Additional data were obtained from clinical records. Recreational Drug-antiretroviral interactions were checked in reference databases. Prevalence was calculated for 5% precision and 95% CI. Crude and adjusted binary logistic regressions were performed to identify associations between recreational Drug use and adherence problems, and between recreational Drug use and high-risk sexual behaviour. Results From the overall sample, 92 participants (44.2%) consumed recreational Drugs over the past 1 year. Of these, 44 (48.8%) had used different types of recreational Drugs in this period. We detected 11 recreational substances, including sildenafil and nitrites. The most consumed Drugs were: cannabis (68.5%), cocaine (45.5%), nitrites (31.5%), sildenafil (28.3) and ecstasy (19.6%). Relevant interactions occurred in 46 (50%) of the individuals consuming Drugs. Recreational Drug Consumption was found to be related to adherence problems with antiretrovirals (OR: 2.51 (95% CI 1.32 to 4.77) p=0.005) and high-risk sexual behaviour (OR: 2.81 (95% CI 1.47 to 5.39) p=0.002). Conclusions Recreational Drugs are frequently used by HIV patients on treatment. Classical Drugs and new substances consumed in sexual context are usual. Recreational Drug Consumption interferes with several clinical outcomes, including potentially relevant interactions between Drugs and antiretrovirals, adherence problems and high-risk sexual behaviour. Thus, there is the urgent need of implementing patient-centred care involving recreational Drug Consumption.
Noe Garin - One of the best experts on this subject based on the ideXlab platform.
-
prevalence and clinical impact of recreational Drug Consumption in people living with hiv on treatment a cross sectional study
BMJ Open, 2017Co-Authors: Noe Garin, Beatriz Zurita, Cesar Velasco, Anna Feliu, Mar Gutierrez, Montserrat Masip, Antonia M ManguesAbstract:Objectives Drug interactions, poor adherence to medication and high-risk sexual behaviour may occur in individuals with HIV using recreational Drugs. Thus, we aimed to assess the prevalence of recreational Drugs use and to explore its clinical impact in HIV patients on treatment. Methods Observational, cross sectional, study conducted in a 700 bed university hospital, Barcelona, Spain. A total of 208 adults living with HIV on treatment were included. A questionnaire was administered by clinical pharmacists, including evaluation of sociodemographic variables, past 12-month Drug Consumption, adherence to antiretrovirals (Simplified Medication Adherence Questionnaire) and high-risk sexual behaviour (condomless sex/multiple partners). Additional data were obtained from clinical records. Recreational Drug-antiretroviral interactions were checked in reference databases. Prevalence was calculated for 5% precision and 95% CI. Crude and adjusted binary logistic regressions were performed to identify associations between recreational Drug use and adherence problems, and between recreational Drug use and high-risk sexual behaviour. Results From the overall sample, 92 participants (44.2%) consumed recreational Drugs over the past 1 year. Of these, 44 (48.8%) had used different types of recreational Drugs in this period. We detected 11 recreational substances, including sildenafil and nitrites. The most consumed Drugs were: cannabis (68.5%), cocaine (45.5%), nitrites (31.5%), sildenafil (28.3) and ecstasy (19.6%). Relevant interactions occurred in 46 (50%) of the individuals consuming Drugs. Recreational Drug Consumption was found to be related to adherence problems with antiretrovirals (OR: 2.51 (95% CI 1.32 to 4.77) p=0.005) and high-risk sexual behaviour (OR: 2.81 (95% CI 1.47 to 5.39) p=0.002). Conclusions Recreational Drugs are frequently used by HIV patients on treatment. Classical Drugs and new substances consumed in sexual context are usual. Recreational Drug Consumption interferes with several clinical outcomes, including potentially relevant interactions between Drugs and antiretrovirals, adherence problems and high-risk sexual behaviour. Thus, there is the urgent need of implementing patient-centred care involving recreational Drug Consumption.
Valerie A Pazsoldan - One of the best experts on this subject based on the ideXlab platform.
-
sexual behavior and Drug Consumption among young adults in a shantytown in lima peru
BMC Public Health, 2009Co-Authors: Juan A Galvezbuccollini, Suzanne L Delea, Phabiola Herrera, Robert H Gilman, Valerie A PazsoldanAbstract:Risky sexual behaviors of young adults have received increasing attention during the last decades. However, few studies have focused on the sexual behavior of young adults in shantytowns of Latin America. Specifically, studies on the association between sexual behaviors and other risk factors for sexually transmitted infections (STI) and HIV/AIDS transmission, such as the Consumption of illicit Drugs or alcohol are scarce in this specific context. The study participants were 393 men and 400 women between 18 and 30 years of age, from a shantytown in Lima, Peru. Data were obtained via survey: one section applied by a trained research assistant, and a self-reporting section. Logistic regression was used to estimate associations between use of any illicit Drug, high-risk sexual behaviors and reported STI symptoms, adjusting for alcohol Consumption level and various socio-demographic characteristics. Among men, age of sexual debut was lower, number of lifetime sexual partners was higher, and there were higher risk types of sexual partners, compared to women. Though consistent condom use with casual partners was low in both groups, reported condom use at last intercourse was higher among men than women. Also, a lifetime history of illicit Drug Consumption decreased the probability of condom use at last sexual intercourse by half. Among men, the use of illicit Drugs doubled the probability of intercourse with a casual partner during the last year and tripled the probability of reported STI symptoms. Drug Consumption is associated with high-risk sexual behaviors and reported STI symptoms in a Lima shantytown after controlling for alcohol Consumption level. Development of prevention programs for risky sexual behaviors, considering gender differences, is discussed.
Juan A Galvezbuccollini - One of the best experts on this subject based on the ideXlab platform.
-
sexual behavior and Drug Consumption among young adults in a shantytown in lima peru
BMC Public Health, 2009Co-Authors: Juan A Galvezbuccollini, Suzanne L Delea, Phabiola Herrera, Robert H Gilman, Valerie A PazsoldanAbstract:Risky sexual behaviors of young adults have received increasing attention during the last decades. However, few studies have focused on the sexual behavior of young adults in shantytowns of Latin America. Specifically, studies on the association between sexual behaviors and other risk factors for sexually transmitted infections (STI) and HIV/AIDS transmission, such as the Consumption of illicit Drugs or alcohol are scarce in this specific context. The study participants were 393 men and 400 women between 18 and 30 years of age, from a shantytown in Lima, Peru. Data were obtained via survey: one section applied by a trained research assistant, and a self-reporting section. Logistic regression was used to estimate associations between use of any illicit Drug, high-risk sexual behaviors and reported STI symptoms, adjusting for alcohol Consumption level and various socio-demographic characteristics. Among men, age of sexual debut was lower, number of lifetime sexual partners was higher, and there were higher risk types of sexual partners, compared to women. Though consistent condom use with casual partners was low in both groups, reported condom use at last intercourse was higher among men than women. Also, a lifetime history of illicit Drug Consumption decreased the probability of condom use at last sexual intercourse by half. Among men, the use of illicit Drugs doubled the probability of intercourse with a casual partner during the last year and tripled the probability of reported STI symptoms. Drug Consumption is associated with high-risk sexual behaviors and reported STI symptoms in a Lima shantytown after controlling for alcohol Consumption level. Development of prevention programs for risky sexual behaviors, considering gender differences, is discussed.
Joan Colom - One of the best experts on this subject based on the ideXlab platform.
-
the social cost of illegal Drug Consumption in spain
Addiction, 2002Co-Authors: Anna Garciaaltes, Josep Ma Olle, Fernando Antonanzas, Joan ColomAbstract:Aims The objective of this study was to estimate the social cost of the Consumption of illegal Drugs in Spain. Design We performed a cost-of-illness study, using a prevalence approximation and a societal perspective. The estimation of costs and consequences referred to 1997. As direct costs we included health-care costs, prevention, continuing education, research, administrative costs, non-governmental organizations and crime-related costs. As indirect costs we included lost productivity associated with mortality and the hospitalization of patients. Estimation of intangible costs was not included. Findings The minimum cost of illegal Drug Consumption in Spain is 88 800 million pesetas (PTA) (467 million dollars). Seventy-seven per cent of the costs correspond to direct costs. Of those, crime-related costs represent 18%, while the largest part corresponds to the health-care costs (50% of direct costs). From the perspective of the health-care system, the minimum cost of illegal Drug Consumption is 44 000 million PTA (231 million dollars). The cost of illegal Drug Consumption represents 0.07% of the Spanish GDP. This gross figure compares with 2250 million PTA (12.5 million dollars) invested in prevention programmes during the same year, and with 12 300 million PTA (68.3 million dollars) spent on specific programmes and resources for the Drug addict population. Conclusions Although there are limitations intrinsic in this type of study and the estimations obtained in the present analysis are likely to be an underestimate of the real cost of this condition, we estimate that illegal Drug Consumption costs the Spanish economy at least 0.2% of GDP.
